Skip to main content
GutCited

عملية البحث

477 أشكال من أبحاث محكّمة

الكل Psyllium Husk Bifidobacterium lactis Fructooligosaccharides (FOS) Lactobacillus plantarum Peppermint Oil Pancreatic Enzymes (Pancrelipase) Curcumin Vitamin A Medium-Chain Triglycerides (MCT Oil) Galactooligosaccharides (GOS) Lactobacillus gasseri Aloe Vera (Inner Leaf Gel) Alpha-Galactosidase Vitamin D L-Glutamine Inulin Ginger Lactase Berberine Omega-3 Fatty Acids (EPA/DHA) Bovine Colostrum Zinc Bifidobacterium bifidum Butyrate (Sodium/Calcium Butyrate) Bacillus coagulans Saccharomyces boulardii Lactobacillus acidophilus N-Acetyl Cysteine (NAC) Bifidobacterium longum
All Types Chart Diagram Photograph Flowchart Forest Plot Micrograph Other
Figure 2. Transmission electron microscopic, TEM, images of mucopenetrative liposomes (A). MP3, cationic liposomes with Pluronic F-127 (B). MP1, neutral liposomes with Pluronic F-127. For formulations’ composition, refer to Table 1.
Figure 3

Figure 2. Transmission electron microscopic, TEM, images of mucopenetrative liposomes (A). MP3, cationic liposomes with Pluronic F-127 (B). MP1, neutral liposomes with Pluronic F-127. For formulations’ composition, refer to Table …

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 3. Diffusion of mucopenetrative liposomal particles from MP1 to MP6 through 1 mm thick sigma mucin type I in a silicon tube maintained at pH 6.0 at 37 ◦C at 1, 2, and 3 hours’ time (n = 3, mean ± SD shown). Abbreviations: MP1 (neutral with Pluronic
Figure 4

Figure 3. Diffusion of mucopenetrative liposomal particles from MP1 to MP6 through 1 mm thick sigma mucin type I in a silicon tube maintained at pH 6.0 at 37 ◦C …

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 5
Figure 5

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 7
Figure 7

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 8
Figure 8

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 9
Figure 9

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 11
Figure 11

Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in …

Figure 2
Figure 2

Fructooligosaccharides for Relieving Functional Constipation: A Systematic Review and Meta-Analysis of Randomized …

Figure 3
Figure 3

Fructooligosaccharides for Relieving Functional Constipation: A Systematic Review and Meta-Analysis of Randomized …

Figure 2
Figure 2

Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro.

Figure 3
Figure 3

Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro.

Figure 4
Figure 4

Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro.

Figure 5
Figure 5

Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro.

Figure 6
Figure 6

Sodium butyrate regulates macrophage polarization by TGR5/β-arrestin2 in vitro.

Figure 1
Figure 1

Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic …

Figure 2. NBCs with potential therapeutic roles in T2D and MASLD.
Figure 3

Figure 2. NBCs with potential therapeutic roles in T2D and MASLD.

Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic …

Figure 1. Main mechanisms of action of functional foods, herbal medicine, and other nutraceuticals in IBS. Each icon next to the medicinal products indicates which of the five main pathophysiological mechanisms of IBS the product targets.
Figure 1

Figure 1. Main mechanisms of action of functional foods, herbal medicine, and other nutraceuticals in IBS. Each icon next to the medicinal products indicates which of the five main pathophysiological …

Functional Foods and Nutraceuticals in Irritable Bowel Syndrome.

Figure 4
Figure 4

Pharmacological effects of different ginger juices on the concurrent symptoms in animal …

Figure 5
Figure 5

Pharmacological effects of different ginger juices on the concurrent symptoms in animal …

Figure 2
Figure 2

Open-label long-term treatment of add-on triheptanoin in adults with drug-resistant epilepsy.

Figure 3
Figure 3

Open-label long-term treatment of add-on triheptanoin in adults with drug-resistant epilepsy.

FIGURE 3 A, Duration on full treatment dose and B the changes in body weight are shown for all participants. B, The changes in body weight (kg) from the beginning of the study until the end of the triheptanoin treatment vs until the end of the full study
Figure 4

FIGURE 3 A, Duration on full treatment dose and B the changes in body weight are shown for all participants. B, The changes in body weight (kg) from the beginning …

Open-label long-term treatment of add-on triheptanoin in adults with drug-resistant epilepsy.

Figure 6
Figure 6

Prophylactic Effect of Bovine Colostrum on Intestinal Microbiota and Behavior in Wild-Type …

Figure 7
Figure 7

Prophylactic Effect of Bovine Colostrum on Intestinal Microbiota and Behavior in Wild-Type …

الصفحة 18 من 20